Demand and Supply of Isotopes Around the World -  From Diverse Perspectives

Watch the Recording Below!

Increasing reliance on medical isotopes for imaging and therapy purposes along with the constraints on the production processes (reactors and accelerators) poses some interesting challenges while also offering new opportunities.  The panel of experts engaged in diverse aspects of isotopes supply chain will share their perspectives and provide a glimpse into the prospects. 

Diverse Perspectives on Demand and Supply of Isotopes Around the World 

Welcome Remarks

Jong Kyung Kim
World Council on Isotopes 


OECD Nuclear Energy Agency (NEA)


Jong Kyung Kim is a professor emeritus in the department of Nuclear Engineering at Hanyang University in Korea.

He had a particular responsibility for the preparation of the national promotion plan for the utilization of radiation and radioisotopes in Korea (2001-2007).He was a commissioner of the Korea Atomic Energy Commission (2010-2013). He was president of Korean Nuclear Society (KNS/ 2013-2014).

He was a member of the Standing Advisory Group on Nuclear Energy (SAGNE/ 2014-2017) of the IAEA. He was the past president of Korea Atomic Energy Research Institute (KAERI/ 2014-2017). He is an executive council (EC) member (2008-2021) and vice-president for congress affairs (2016-2021) of the International Radiation Protection Association (IRPA). He is currently serving as president of the 15th International Congress of IRPA, IRPA 15. He served on the International Monitoring and Steering Committee (IMSC) for 6ICI and the Executive Committee (EC) for 7ICI-10ICI. He is the president of WCI (2020.2-2022.6).

He has a bachelor’s degree from SUNY at Buffalo in nuclear engineering and a master’s degree and Ph.D. (1986) in the same discipline from the University of Michigan in USA. 

Mr Magwood took up his duties as Director-General of the Nuclear Energy Agency (NEA) on1 September 2014. He has extensive experience in both the regulatory and developmental aspects of nuclear energy, including at the international level. From 2010 to 2014, he served as one of the five Commissioners appointed by the US President and confirmed by the US Senate to the US Nuclear Regulatory Commission (NRC). 

While a commissioner, he advocated the importance of nuclear regulatory independence and the necessity of maintaining strong, credible and technically sound nuclear regulation in the United States and all countries that use nuclear power.

During his tenure, he established the Idaho National Laboratory; created activities that reversed the decline of US nuclear technology education; and launched important initiatives such as the Generation IV International Forum (GIF)and the US “Nuclear Power 2010,” which helped restart nuclear plant construction in the United States. He was also
actively involved in the work of the NEA, serving as a Steering Committee Bureau member from 1999 to 2005, including a term as Chair of the Steering Committee from 2004to 2005.

Prior to his appointment at the NRC, from 2005 to 2010 he provided independent strategic and policy advice to US and international clients on energy, environment, education, and technology policy issues. From 1998 to 2005, Mr Magwood was Director of the US Government’s civilian nuclear energy programme at the US Department of Energy (DOE).

Prior to his experience at the DOE, Mr Magwood managed electric utility research and nuclear policy programmes at the Edison Electric Institute in Washington, DC, and was a scientist at Westinghouse Electric Corporation in Pittsburgh, Pennsylvania. Mr Magwood, a US national, holds Bachelor degrees in Physics and English from Carnegie Mellon University and a Master of Fine Arts from the University of Pittsburgh.

Your Industry Experts

Recorded Presentation
Amir R. Jalilian
Radioisotope & Radiopharmaceutical Chemist, International Atomic Energy Agency (IAEA), Austria 

Professor Amir R. Jalilian has a PharmD. degree (1995), Ph.D. degree in Radiopharmacy (2000) followed by postdoctoral fellowships from University of Alberta, Canada and Yale School of Medicine, CT, USA. Until 2015, he was active in the development of new radiopharmaceuticals leading to completion of clinical trials and the marketing of six radiopharmaceuticals. He has published around 300 scientific papers in peer-viewed journals and five books in various languages and supervised more than 50 MSc and PhD theses. In 2015, he joined the Nuclear Sciences and Application Department, International Atomic Energy Agency (IAEA), Vienna Headquarters, Austria as a Radioisotope/Radiopharmaceutical Chemist. He is leading four IAEA international Collaborated Research Projects (CRP) on the topic of  radioisotope and radiopharmaceutical production.

Ram Mullur
VP Isotopes Business, Canadian Nuclear Laboratories

Ram Mullur is the Vice President of CNL Isotopes Business. In his role as a CNL executive, Ram is currently leading CNL’s Ac-225 program initiatives on product development, facility design and corporate development fronts. 
Ram is an accomplished executive with more than 25 years of broad industry experience, a proven track-record in business development, leadership and charting a growth trajectory through new products. Through his work in the industry, Ram has a deep understanding of the Global medical isotopes and radiopharmaceuticals landscape.

 Prior to CNL, Ram served as the Director and Head of Business Development at Jubilant Draxlmage, a global leader in radiopharmaceuticals, where he was responsible for expanding the company’s commercial business into new products and technologies in radiopharmaceutical field. This experience also included leading acquisition, investment and licensing initiatives, negotiating business contracts, pursuing strategic partnerships. Ram advanced key products in the company’s development pipeline to their commercial phase including leading the key actions in securing FDA and Health Canada approvals. He was instrumental in the building of a vibrant pipeline of growth products. Ram developed and executed external business partnerships for radiopharmaceutical products.

Jehanne Gillo
Director, The DOE Isotope Program, Department of Energy, US  

Dr. Jehanne Gillo has worked at the Department of Energy (DOE) since February 2000 when she joined the DOE Office of Science as Program Manager for Nuclear Physics Facilities & Instrumentation.  Dr. Gillo became part of the Federal Senior Executive Service in 2005 and was appointed as Director of the Facilities and Project Management Division in the Office of Nuclear Physics, where she is responsible for the operations of all nuclear physics scientific user facilities, large construction projects, fabrication of scientific instrumentation, accelerator research and development, and the nuclear physics SBIR/STTR program.  Since 2009, she has also been the Director of the DOE Isotope Program. In 2020, she led the DOE Isotope Program to be organized into a standalone Office at the DOE, now called the Office of Isotope R&D and Production.

Dr. Gillo has been awarded the Presidential award and two Secretarial awards during her federal career. She was awarded the 2016 Presidential Rank of Meritorious Executive Award for her accomplishments in the Office of Nuclear Physics. She received the 2016 Secretary’s Achievement Award for her efforts on the Joint Comprehensive Plan of Action (JCPOA) Support Team. She received the Secretary of Energy Excellence Award in October 2012 for her management of the DOE Isotope Program. Dr. Gillo serves on several White House committees and Interagency Groups, including as Chair of the He-3 Interagency Working Group that reports to the White House National Security Staff.  

Pieter Louw
Group Executive: Production, NTP Radioisotopes, South Africa 

As Production Group Executive Pieter Louw is responsible for the safe and reliable production of all NTP Radioisotopes SOC Ltd’s products in full compliance with all regulatory requirements related to nuclear safety and medical product manufacture.  These include API’s (Mo-99, I-131 and Lu-177), Radiopharmaceuticals (Tc-99m generators, I-131 products and FDG), Industrials (Ir-192) and Irradiation Services performed at the SAFARI-1 research reactor.  Piet furthermore assumes responsibility for the marketing and sales function at NTP.  He started his career at Necsa/NTP in 1983 and has extensive technical, commercial and strategic knowledge of NTP, its people, markets, industry, regulators, customers and competitors.  

Renata Mikołajczak
Director’s Plenipotentiary for Research and Scientific Cooperation at Radioisotope Centre, POLATOM, Poland
(Chair Track 1 11ICI)

Professor Renata Mikolajczak holds the degrees of DSc in Medical Biology from Warsaw Medical University, PhD in Physics from the Institute of Atomic Energy, Swierk, and MSc in Chemical Engineering from Technical University in Szczecin, Poland. She completed a two years IAEA fellowship in Analytical Chemistry at Safeguards Analytical Laboratory, Seibersdorf, Austria. With over 33 years in the field of radioisotope and radiopharmaceutical development in Poland she is currently coordinating the research activity of Radioisotope Centre POLATOM, National Centre for Nuclear Research. She is a member of the expert group, PRP Working Party - Precursors for Radiopharmaceutical Preparations,  European Pharmacopoeia of EDQM, and of the IAEA’s Standing Advisory Group on Nuclear Applications (SAGNA).



c/o Venue West Conference Services
#449-1231 Pacific Boulevard
Vancouver, BC V6Z 0E2, Canada



© Copyright 2023 Venue West Conference Services Ltd.
Disclaimer: The information contained in this website is for general information purposes only. The information is provided by Venue West Conference Services and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk. In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website. Through this website you are able to link to other websites which are not under the control of Venue West Conference Services. We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them. Every effort is made to keep the website up and running smoothly. However, Venue West Conference Services takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.